No Silver Bullet, ISPE Survey Confirms: Drug Shortages Require Shotgun Approach
This article was originally published in The Gold Sheet
Executive Summary
Industry agrees FDA could help ameliorate drug shortages with quicker approval of new lines and relaxed enforcement, ISPE survey shows. There’s less enthusiasm for preventing shortages with backup contract manufacturers.
You may also be interested in...
Manufacturers Urged To Prevent Drug Shortages By Reducing Quality Risks
As the main cause of drug shortages is poor manufacturing quality, the best way to prevent them is to get ahead of the curve on quality, says a Pew/ISPE industry survey report.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.